Skip to main content
. 2020 Aug 31;288(7):2103–2118. doi: 10.1111/febs.15523

Fig. 3.

Fig. 3

Schemes of (A) a tandem CAR based on two scFvs, (B) a tandem 'loop' CAR having a special configuration of the CD19 and CD22 scFv (CD19 VL‐CD22 VH‐CD22 VL‐CD19 VH), and (C) a tandem CAR based on two engineered binding scaffolds.